Zentalis Non Current Liabilities Total from 2010 to 2024
| ZNTL Stock | USD 3.63 0.15 4.31% |
Non Current Liabilities Total | First Reported 2019-12-31 | Previous Quarter 42.4 M | Current Value 41.5 M | Quarterly Volatility 35.7 M |
Check Zentalis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zentalis Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 469.1 K, Interest Income of 469.1 K or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 23.9 K, Dividend Yield of 0.0 or PTB Ratio of 2.15. Zentalis financial statements analysis is a perfect complement when working with Zentalis Pharmaceuticals Valuation or Volatility modules.
Zentalis | Non Current Liabilities Total |
Latest Zentalis Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Zentalis Pharmaceuticals Llc over the last few years. It is Zentalis Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zentalis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Zentalis Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 13,148,193 | |
| Geometric Mean | 5,555,886 | |
| Coefficient Of Variation | 140.17 | |
| Mean Deviation | 15,271,217 | |
| Median | 2,484,000 | |
| Standard Deviation | 18,430,233 | |
| Sample Variance | 339.7T | |
| Range | 46.2M | |
| R-Value | 0.73 | |
| Mean Square Error | 171.3T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 3,005,094 | |
| Total Sum of Squares | 4755.4T |
Zentalis Non Current Liabilities Total History
About Zentalis Pharmaceuticals Financial Statements
Zentalis Pharmaceuticals investors utilize fundamental indicators, such as Non Current Liabilities Total, to predict how Zentalis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 44.9 M | 27.5 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Zentalis Pharmaceuticals Correlation against competitors. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Revenue Per Share 0.572 | Return On Assets (0.25) | Return On Equity (0.43) |
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.